Abstract
Spinal and Bulbar Muscular Atrophy (SBMA), also known as Kennedy's disease, is a rare adult-onset lower motor neuron disorder with a classic X-linked inheritance pattern. It is caused by the abnormal expansion of the CAG-repeat tract in the androgen receptor gene. Despite important progress in the understanding of the molecular pathogenesis and the availability of a broad set of model organisms, successful translation of these insights into clinical interventions remains elusive. Here we review the available information on clinical trials in SBMA and discuss the challenges and pitfalls that impede therapy development. Two important factors are the variability of the complex neuro-endocrinological phenotype and the comparatively low incidence of the disease that renders recruitment for clinical trials demanding. We propose that these challenges can be and need to be overcome by fostering closer collaborations between clinical research centers, the patient communities and the industry and non-industry sponsors of clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atsuta N (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129:1446–1455. doi:10.1093/brain/awl096
Banno H (2012) Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy. Arch Neurol 69:436. doi:10.1001/archneurol.2011.2308
Banno H, Adachi H, Katsuno M et al (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520–526. doi:10.1002/ana.20735
Banno H, Katsuno M, Suzuki K et al (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140–150. doi:10.1002/ana.21540
Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 15005–21. doi:10.1038/nrdp.2015.5
Borowsky B, Sampaio C (2014) Experimental therapeutics: moving forward in clinical trials. In: Bates GP, Tabrizi SJ, Jones L (eds) Huntington's disease, 4th edn. Oxford University Press, Oxford, p 462–502
Chio A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118–130. doi:10.1159/000351153
Fernández-Rhodes LE BSNADK, MD MJW et al (2011) Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 10:140–147. doi:10.1016/S1474-4422(10)70321-5
Fischbeck KH (2012) Developing treatment for spinal and bulbar muscular atrophy. Prog Neurobiol 99:257–261. doi:10.1016/j.pneurobio.2012.05.012
Fratta P, Nirmalananthan N, Masset L et al (2014) Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology 82:2077–2084. doi:10.1212/WNL.0000000000000507
Hashizume A, Katsuno M, Suzuki K et al (2015) A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord 25:554–562. doi:10.1016/j.nmd.2015.03.008
Katsuno M, Adachi H, Doyu M et al (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768–773. doi:10.1038/nm878
Katsuno M, Banno H, Suzuki K et al (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:875–884. doi:10.1016/S1474-4422(10)70182-4
Katsuno M, Tanaka F, Adachi H et al (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99:246–256. doi:10.1016/j.pneurobio.2012.05.007
La Spada AR, Wilson EM, Lubahn DB et al (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77–79. doi:10.1038/352077a0
Li M, Nakagomi Y, Kobayashi Y et al (1998) Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 153:695–701. doi:10.1016/S0002-9440(10)65612-X
Lynch GS, Ryall JG (2008) Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 88:729–767. doi:10.1152/physrev.00028.2007
Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316–328. doi:10.1016/j.neuron.2009.07.019
Papanikolaou T, Ellerby LM (2009) IGF-1: elixir for motor neuron diseases. Neuron 63:277–278. doi:10.1016/j.neuron.2009.07.024
Pennuto M, Greensmith L, Pradat P-F et al (2015) 210th ENMC International Workshop: research and clinical management of patients with spinal and bulbar muscular atrophy, 27–29 March, 2015, Naarden, The Netherlands. Neuromuscul Disord 25:802–812. doi:10.1016/j.nmd.2015.06.462
Preisler N, Andersen G, Thøgersen F et al (2009) Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology 72:317–323. doi:10.1212/01.wnl.0000341274.61236.02
Querin G, D’Ascenzo C, Peterle E et al (2013) Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology 80:2095–2098. doi:10.1212/WNL.0b013e318295d766
Rocchi A, Pennuto M (2013) New routes to therapy for spinal and bulbar muscular atrophy. J Mol Neurosci. doi:10.1007/s12031-013-9978-7
Sahashi K, Katsuno M, Hung G et al (2015) Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 24:5985–5994. doi:10.1093/hmg/ddv300
Shrader JA, Kats I, Kokkinis A et al (2015) A randomized controlled trial of exercise in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol 2:739–747. doi:10.1002/acn3.208
Sveen M-L, Jeppesen TD, Hauerslev S et al (2007) Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology 68:59–61. doi:10.1212/01.wnl.0000250358.32199.24
Willis TA, Hollingsworth KG, Coombs A et al (2013) Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 8:e70993–7. doi:10.1371/journal.pone.0070993
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Weydt, P., Sagnelli, A., Rosenbohm, A. et al. Clinical Trials in Spinal and Bulbar Muscular Atrophy—Past, Present, and Future. J Mol Neurosci 58, 379–387 (2016). https://doi.org/10.1007/s12031-015-0682-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-015-0682-7